Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

[Rheumatic disorders observed in HIV infected patients undergoing highly active antiretroviral therapy (HAART): a 366 case prospective study in Burkina Faso].

Ouédraogo DD, Lompo CP, Tiéno H, Bognounou R, Diendéré AE, Sawadogo A, Zoungrana L, Drabo JY.

Med Trop (Mars). 2010 Aug;70(4):345-8. French.

PMID:
22368930
2.

[Metabolic disorders and cardiovascular risk factors observed in patients infected by the HIV with antiretroviral therapy in Burkina Faso].

Bognounou R, Diendéré A, Diallo I, Tieno H, Guira O, Ouedraogo DD, Drabo YJ.

Med Trop (Mars). 2011 Dec;71(6):626-7. French.

PMID:
22393637
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study.

Kouanda S, Meda IB, Nikiema L, Tiendrebeogo S, Doulougou B, Kaboré I, Sanou MJ, Greenwell F, Soudré R, Sondo B.

AIDS Care. 2012;24(4):478-90. doi: 10.1080/09540121.2011.630353.

PMID:
22148973
5.
6.
7.

Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso.

Nadembega WM, Giannella S, Simpore J, Ceccherini-Silberstein F, Pietra V, Bertoli A, Pignatelli S, Bellocchi MC, Nikiema JB, Cappelli G, Bere A, Colizzi V, Perno CP, Musumeci S.

J Med Virol. 2006 Nov;78(11):1385-91.

PMID:
16998878
8.

Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.

Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.

HIV Med. 2007 Mar;8(2):75-9.

9.

Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso.

Dembélé M, Saleri N, Carvalho AC, Saouadogo T, Hien AD, Zabsonre I, Koala ST, Simporé J, Matteelli A.

Int J Tuberc Lung Dis. 2010 Mar;14(3):318-23.

PMID:
20132623
10.

[Arthropathic and degenerative pathology in rheumatology patients in Burkina Faso].

Ouédraogo DD, Tiéno H, Nacoulma EW, Yaméogo S, Kouldiaty J, Traoré R, Drabo JY.

Med Trop (Mars). 2010 Aug;70(4):411-2. French.

PMID:
22368949
11.

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.

van Leth F, Wit FW, Reiss P, Schattenkerk JK, van der Ende ME, Schneider MM, Mulder JW, Frissen PH, de Wolf F, Lange JM.

HIV Med. 2004 Mar;5(2):74-81.

12.

The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy.

Jevtović DJ, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.

HIV Med. 2005 Mar;6(2):140-3.

13.

[Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso].

Millogo A, Lankoandé D, Yaméogo I, Yaméogo AA, Sawadogo AB.

Bull Soc Pathol Exot. 2008 Feb;101(1):11-3. French.

PMID:
18431998
14.

Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study.

Nicolatou-Galitis O, Velegraki A, Paikos S, Economopoulou P, Stefaniotis T, Papanikolaou IS, Kordossis T.

Oral Dis. 2004 May;10(3):145-50.

PMID:
15089923
15.
16.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
17.

Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.

Oette M, Kaiser R, Däumer M, Akbari D, Fätkenheuer G, Rockstroh JK, Stechel J, Rieke A, Mauss S, Schmalöer D, Göbels K, Vogt C, Wettstein M, Häussinger D.

Eur J Med Res. 2004 May 28;9(5):273-8.

PMID:
15257882
18.

Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002).

Martin K, Lawson-Ayayi S, Miremont-Salamé G, Blaizeau MJ, Balestre E, Lacoste D, Ragnaud JM, Malvy D, Dupon M, Mercié P, Schaeverbeke T, Haramburu F, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine..

HIV Med. 2004 Nov;5(6):421-6.

19.

Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.

Lorenzen T, Walther I, Stoehr A, Salzberger B, Plettenberg A; Radata Study Group..

Infection. 2009 Dec;37(6):528-33. doi: 10.1007/s15010-009-9022-6.

PMID:
19826762
20.

Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso.

Kouanda S, Tougri H, Cisse M, Simpore J, Pietra V, Doulougou B, Ouedraogo G, Ouedraogo CM, Soudre R, Sondo B.

AIDS Care. 2010 Jul;22(7):843-50. doi: 10.1080/09540120903499204.

PMID:
20635248
Items per page

Supplemental Content

Support Center